Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Ebitda Margin CompressionResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.7%Reaction day

₹610.00

prior close

₹584.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-9.6% vs market

Pharmaceuticals peers, median of 147sector-0.1%-9.6% vs sector

On the reaction day the stock moved 9.6 pts less than Nifty Microcap 250 and 9.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-2.8

15m

-3.3

30m

-2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.7-0.1-9.6-0.1-9.6

Next day

-8.5+0.5-9.0-0.3-8.2

-8.5+1.1-9.6-0.0-8.5

-10.0+1.0-11.0+0.2-10.1

-9.8+1.4-11.2+0.1-10.0

-11.3+1.7-13.0+0.5-11.8

-9.9+2.1-12.0-0.2-9.7

15d

-1.8+3.9-5.7+1.4-3.2

-8.9+1.2-10.1-2.7-6.1

-9.1+6.7-15.8+1.5-10.6

-8.6+2.7-11.2-1.0-7.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lincoln Pharmaceuticals reported FY25 standalone revenue from operations of ₹623.23 crore, up about 7.4% from ₹580.55 crore in FY24, while total income rose 5% to ₹645.71 crore. However, profitability took a hit — net profit fell 11.7% to ₹82.34 crore and EBITDA declined 7.7% to ₹123.97 crore, reflecting margin pressure from higher costs. EPS stood at ₹41.11 versus ₹46.58 last year. For Q4 FY25 alone, revenue grew sharply to ₹168.18 crore but net profit dropped to ₹11.58 crore from ₹18.60 crore. The board has recommended a dividend of ₹1.80 per share (18%) for FY25. The auditor issued an unmodified (clean) opinion, and the company remains net debt-free with operating cash flow improving strongly to ₹93.02 crore from ₹63.24 crore.

Likely market impact

Mixed bag for shareholders — top-line growth is healthy and dividend is maintained, but the sharp fall in profits and EBITDA despite higher revenue signals margin compression that may concern investors. The company's ₹750 crore FY26 revenue target and improving operating cash flows are positives, but watch for cost discipline to restore profitability.